EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 208 filers reported holding EXELIXIS INC in Q3 2016. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $5,339 | -1.1% | 225 | 0.0% | 0.00% | – |
| Q4 2023 | $5,397 | +9.8% | 225 | 0.0% | 0.00% | – |
| Q3 2023 | $4,916 | +14.4% | 225 | 0.0% | 0.00% | – |
| Q2 2023 | $4,299 | -1.6% | 225 | 0.0% | 0.00% | – |
| Q1 2023 | $4,367 | +21.0% | 225 | 0.0% | 0.00% | – |
| Q4 2022 | $3,609 | +20.3% | 225 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | -96.8% | 225 | -98.1% | 0.00% | -100.0% |
| Q2 2016 | $93,000 | +93.8% | 12,000 | 0.0% | 0.00% | – |
| Q1 2016 | $48,000 | -28.4% | 12,000 | 0.0% | 0.00% | – |
| Q4 2015 | $67,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |